Business
Malaria Human Challenge Model
Malaria Human Challenge Model.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9130H\n Open Orphan PLC\n 09 August 2021\n \n \n \n \n 9 August 2021\n \n \n \n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n \n \n \n Development of Controlled Human Malaria Infection Human Challenge Study\n \n \n hVIVO to assist in the advancement of antimalarial drug and vaccine candidates from November 2021\n \n \n \n \n \n Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in testing vaccines and antivirals using human challenge clinical trials, announces\n \n that its subsidiary, \n hVIVO\n ,\n has developed a \n Controlled Human Malaria Infection (\"CHMI\") challenge model\n , both strengthening and further diversifying the Company's world leading portfolio of viral challenge study models. The Malaria challenge model will assist in the advancement of antimalarial drug and vaccine candidates from November 2021. \n Results from CHMI modelling of drug and vaccine efficacy have previously shown good translation into the field. \n \n \n \n \n \n Malaria is a serious and life-threatening disease prevalent across much of tropical and sub-tropical Asia, South America and Sub-Saharan Africa. Due to increasing resistance to current antimalarial regimens, new drugs are required as both stand-alone and partner therapies to address a growing unmet medical need. In addition, novel combinations of existing drugs may be required to fill the gap until pipeline candidates can be safely progressed to market. New drugs and combination therapies are required to not only reduce mortality and morbidity in susceptible, primarily paediatric populations, but also to help the move towards a greater goal of malaria elimination.\n \n \n \n \n \n hVIVO has secured access\n to a unique, GMP-manufactured P. falciparum sporozoite challenge agent (\"PfSPZ Challenge\") for use in its malaria challenge studies. PfSPZ Challenge has been used in multiple clinical trials in the United Kingdom, United States, Europe, Indonesia and Africa. As of June 2021, 1,204 volunteers have received 2,011 doses of PfSPZ Challenge (NF54) with no unresolved serious adverse event, sequelae, or deaths to date. \n Controlled Human Malaria Infection \n by Direct Venous Inoculation has largely replaced the traditional method of...